Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Pancreatic Ductal × Lead × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Brain Neoplasms 3 Neoplasms 2 Lung Neoplasms 2 Thrombophilia 1 Stomatitis 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Periodontitis 1 Neoplasms, Plasma Cell 1 Motor Activity 1 Liver Neoplasms 1 Liver Diseases 1 Head and Neck Neoplasms 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Febrile Neutropenia 1 EGFR-Mutant Lung Cancer 1 Deglutition Disorders 1 Communication Disorders 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Blood Coagulation Disorders 1 Adenocarcinoma 1

Interventions

Gemcitabine 15 130-nm albumin-bound paclitaxel 10 Albumin-Bound Paclitaxel 7 Oxaliplatin 5 Paclitaxel 4 Leucovorin 4 Fluorouracil 4 Carboplatin 4 Cisplatin 3 Cetuximab 3 Bevacizumab 3 pembrolizumab 2 napabucasin 2 Pemetrexed 2 PEGPH20 2 MK-4721 2 Irinotecan 2 tremelimumab 1 selinexor 1 relacorilant 1 ponatinib 1 neratinib 1 irinotecan sucrosofate 1 folfirinox 1 ensituximab 1 durvalumab 1 contrast agent BR1 1 cobimetinib 1 ceritinib 1 cc-486 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡